BRPI1014865A2 - "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica" - Google Patents
"composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica"Info
- Publication number
- BRPI1014865A2 BRPI1014865A2 BRPI1014865A BRPI1014865A BRPI1014865A2 BR PI1014865 A2 BRPI1014865 A2 BR PI1014865A2 BR PI1014865 A BRPI1014865 A BR PI1014865A BR PI1014865 A BRPI1014865 A BR PI1014865A BR PI1014865 A2 BRPI1014865 A2 BR PI1014865A2
- Authority
- BR
- Brazil
- Prior art keywords
- formulation
- pharmaceutical composition
- nitrocathecol
- derivatives
- manufacturing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16577809P | 2009-04-01 | 2009-04-01 | |
US61/165,778 | 2009-04-01 | ||
PCT/PT2010/000014 WO2010114404A1 (en) | 2009-04-01 | 2010-03-31 | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI1014865A2 true BRPI1014865A2 (pt) | 2016-05-03 |
BRPI1014865B1 BRPI1014865B1 (pt) | 2020-03-17 |
Family
ID=42225014
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI1014865-5A BRPI1014865B1 (pt) | 2009-04-01 | 2010-03-31 | Composição que compreende grânulos compreendendo 2,5- dicloro- 3- (5- (3,4- dihidróxi- 5- nitrofenil)- 1,2,4- oxadiazol- 3- il)- 4,6- dimetilpiridina 1- óxido e formulação farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (4) | US9132094B2 (pt) |
EP (1) | EP2413912B1 (pt) |
JP (2) | JP5864409B2 (pt) |
KR (4) | KR102329271B1 (pt) |
CN (2) | CN105878242A (pt) |
AU (1) | AU2010231961B2 (pt) |
BR (1) | BRPI1014865B1 (pt) |
CA (1) | CA2757411C (pt) |
DK (1) | DK2413912T3 (pt) |
ES (1) | ES2730678T3 (pt) |
MX (1) | MX340360B (pt) |
PL (1) | PL2413912T3 (pt) |
PT (1) | PT2413912T (pt) |
RU (2) | RU2701731C2 (pt) |
TR (1) | TR201908590T4 (pt) |
WO (1) | WO2010114404A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITMI20022394A1 (it) | 2002-11-13 | 2004-05-14 | Bracco Spa | Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche. |
ITMI20110713A1 (it) | 2011-04-29 | 2012-10-30 | Bracco Imaging Spa | Processo per la preparazione di un derivato solfatato di3,5-diiodo-o-[3-iodofenil]-l-tirosina |
US8168793B2 (en) | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
ES2597705T3 (es) | 2007-01-31 | 2017-01-20 | Bial - Portela & Ca., S.A. | Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico |
ES2565080T3 (es) | 2008-03-17 | 2016-03-31 | Bial-Portela & Ca, S.A. | Formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol |
PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
US20140045900A1 (en) * | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
AU2012238665B2 (en) * | 2011-04-08 | 2016-09-29 | Bracco Imaging Spa | Process for the preparation of a sulfated derivative of 3,5-diiodo-O-[3-iodophenyl]-L-tyrosine |
PL2791134T3 (pl) | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
JP2018500300A (ja) | 2014-11-28 | 2018-01-11 | ノヴィファーマ,エス.アー. | パーキンソン病を遅延させるための医薬 |
US20200170291A1 (en) * | 2017-05-23 | 2020-06-04 | Particle Dynamics International, Llc | Processes for producing lactitol granulates and granulates produced thereby |
WO2020072886A1 (en) | 2018-10-05 | 2020-04-09 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
EP3860602A1 (en) | 2018-10-05 | 2021-08-11 | Neurocrine Biosciences, Inc. | Methods for the administration of comt inhibitors |
AU2021235850A1 (en) | 2020-03-13 | 2022-10-06 | BIAL - PORTELA & Cª, S.A. | Micronised opicapone |
GB202011709D0 (en) | 2020-07-28 | 2020-09-09 | Bial Portela & Ca Sa | Solid dispersion of opicapone |
GB202016425D0 (en) | 2020-10-16 | 2020-12-02 | Bial Portela & Ca Sa | Treatment regimens for parkinson's disease |
WO2022131944A1 (en) | 2020-12-17 | 2022-06-23 | Bial-Portela & Ca., S.A. | Treatment regimens for early idiopathic parkinson's disease |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1532178A (en) * | 1921-07-25 | 1925-04-07 | Louis A Godbold | Lubricator |
FR1260080A (fr) | 1960-03-22 | 1961-05-05 | Materiel De Forage Soc De Fab | Trépan à molettes étanche |
IL31990A (en) * | 1968-04-26 | 1974-05-16 | Chinoin Gyogyszer Es Vegyeszet | Pyridyl 1,2,4-oxadiazole derivatives,process for the preparation thereof and pharmaceutical compositions containing same |
US4022901A (en) | 1975-03-05 | 1977-05-10 | E. R. Squibb & Sons, Inc. | 3-Pyridinyl-5-isothiocyanophenyl oxadiazoles |
US4085563A (en) * | 1977-01-31 | 1978-04-25 | Campbell Soup Company | Cookie dispensing apparatus |
US4264573A (en) * | 1979-05-21 | 1981-04-28 | Rowell Laboratories, Inc. | Pharmaceutical formulation for slow release via controlled surface erosion |
US4386668A (en) | 1980-09-19 | 1983-06-07 | Hughes Tool Company | Sealed lubricated and air cooled rock bit bearing |
US4368668A (en) * | 1981-05-15 | 1983-01-18 | Veb Kombinat Polygraph "Werner Lamberz" Leipzig | Printing plate mounting arrangement |
US5236952A (en) * | 1986-03-11 | 1993-08-17 | Hoffmann-La Roche Inc. | Catechol derivatives |
DK175069B1 (da) | 1986-03-11 | 2004-05-24 | Hoffmann La Roche | Pyrocatecholderivater |
YU213587A (en) * | 1986-11-28 | 1989-06-30 | Orion Yhtymae Oy | Process for obtaining new pharmacologic active cateholic derivatives |
DE3840954A1 (de) | 1988-12-05 | 1990-06-07 | Shell Int Research | Herstellung von 2-chlornicotinsaeureestern |
EP0462639A1 (en) | 1990-06-05 | 1991-12-27 | Shell Internationale Researchmaatschappij B.V. | Preparation of 2-chloropyridine derivatives |
ES2066092T3 (es) | 1990-11-29 | 1995-03-01 | Wei Ming Pharmaceutical Mfg Co | Coadyuvante para la formacion directa de comprimidos. |
CA2126976A1 (en) | 1991-12-31 | 1993-07-08 | Hisashi Takasugi | Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity |
FR2730322B1 (fr) | 1995-02-02 | 1997-04-30 | Imago | Monture de lunettes metallique |
US6361794B1 (en) | 1996-06-12 | 2002-03-26 | Basf Corporation | Method of making ibuprofen and narcotic analgesic composition |
DE19628617A1 (de) | 1996-07-16 | 1998-01-22 | Basf Ag | Direkttablettierhilfsmittel |
US6206110B1 (en) * | 1996-09-09 | 2001-03-27 | Smith International, Inc. | Protected lubricant reservoir with pressure control for sealed bearing earth boring drill bit |
PL343593A1 (en) | 1998-03-27 | 2001-08-27 | Upjohn Co | Use of cabergoline in the treatment of restless legs syndrome |
AU762245B2 (en) * | 1998-09-18 | 2003-06-19 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
GB2344819A (en) | 1998-12-18 | 2000-06-21 | Portela & Ca Sa | 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones |
FI109453B (fi) | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
IL131037A (en) | 1999-07-22 | 2004-06-20 | Israel Atomic Energy Comm | Method for making threedimensional photonic band-gap crystals |
EP1210344B1 (en) | 1999-08-19 | 2005-10-19 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6660753B2 (en) * | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
JP3850189B2 (ja) * | 1999-10-13 | 2006-11-29 | 信越化学工業株式会社 | 固形製剤とその製造方法 |
FI20000635A0 (fi) | 2000-03-17 | 2000-03-17 | Orion Yhtymae Oyj | COMT-inhibiittoreiden käyttö analgeettina |
SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | Axon Chemicals Bv | New chemical compounds and their use in therapy |
DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
GB2363792A (en) | 2000-06-21 | 2002-01-09 | Portela & Ca Sa | Nitrocatechols |
WO2002017175A1 (fr) | 2000-08-24 | 2002-02-28 | Sagawa Express Co., Ltd. | Procede de paiement par carte pour facturation de service concernant une distribution ou un transport physiques |
CN1166626C (zh) | 2000-08-30 | 2004-09-15 | 李凌松 | 三或四取代苯基化合物、其制备方法及应用 |
JP2004532611A (ja) * | 2000-11-28 | 2004-10-28 | ザイモジェネティクス,インコーポレイティド | サイトカイン受容体zcytor19 |
WO2002051442A1 (fr) | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
US20040097555A1 (en) * | 2000-12-26 | 2004-05-20 | Shinegori Ohkawa | Concomitant drugs |
US7867516B2 (en) | 2001-01-29 | 2011-01-11 | Shionogi & Co., Ltd. | Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient |
PL369598A1 (en) | 2001-02-21 | 2005-05-02 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
US6761905B2 (en) * | 2001-05-01 | 2004-07-13 | Wei Ming Pharmaceutical Mfg. Co., Ltd. | Process for the preparation of direct tabletting formulations and aids |
US20030208067A1 (en) | 2001-05-30 | 2003-11-06 | Cao Sheldon Xiaodong | Inhibitors of protein kinase for the treatment of disease |
MXPA03011196A (es) * | 2001-06-08 | 2004-10-28 | Cytovia Inc | 3-aril-5-aril-[1,2,4]-oxadiazoles sustituidos y analogos. |
US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
KR20040029325A (ko) | 2001-07-26 | 2004-04-06 | 메르크 파텐트 게엠베하 | 2-[5-(4-플루오로페닐)-3-피리딜메틸아미노메틸]-크로만및 이의 생리학적으로 허용가능한 염의 신규한 용도 |
JP4379853B2 (ja) * | 2001-10-05 | 2009-12-09 | 惠民製藥股▲分▼有限公司 | 直接錠剤化用調合物および補助剤の調合方法 |
JP2006516250A (ja) * | 2002-12-18 | 2006-06-29 | サイトビア インコーポレイティッド | カスパーゼ活性化剤およびアポトーシス誘導物質としての3,5−二置換−[1,2,4]−オキサジアゾールおよびそれらの誘導体ならびにそれらの使用 |
WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
US7226920B2 (en) | 2003-08-06 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Aminotriazole compounds useful as inhibitors of protein kinases |
DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
EP1673071A1 (en) | 2003-09-29 | 2006-06-28 | Novo Nordisk Femcare AG | Improved stability of progestogen formulations |
US7300406B2 (en) * | 2003-09-30 | 2007-11-27 | Carter Vandette B | Medical examination apparatus |
GB0325956D0 (en) * | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
WO2005105780A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of rock and other protein kinases |
EP1625849A1 (en) | 2004-08-09 | 2006-02-15 | Liconsa, Liberacion Controlada de Sustancias Activas, S.A. | Pharmaceutical composition comprising drospirenone and ethynylestradiol |
GB0510143D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
JP4717414B2 (ja) * | 2004-11-08 | 2011-07-06 | 富田製薬株式会社 | 低融点薬剤含有顆粒、およびこれを用いて製造した錠剤 |
US20060173074A1 (en) | 2004-11-10 | 2006-08-03 | Juha Ellmen | Treatment of restless legs syndrome |
EP1827453A1 (en) | 2004-12-06 | 2007-09-05 | Themis Laboratories Private Limited | Sulfonylurea compositions and a process for its preparation |
US20080051441A1 (en) * | 2004-12-28 | 2008-02-28 | Astrazeneca Ab | Aryl Sulphonamide Modulators |
EP1833804A1 (en) | 2004-12-28 | 2007-09-19 | AstraZeneca AB | Aryl sulphonamide modulators |
CA2606087A1 (en) | 2005-04-26 | 2006-11-02 | Neurosearch A/S | Novel oxadiazole derivatives and their medical use |
US20060257473A1 (en) * | 2005-05-11 | 2006-11-16 | Porranee Puranajoti | Extended release tablet |
GB0510139D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
WO2006132914A2 (en) | 2005-06-03 | 2006-12-14 | Abbott Laboratories | Cyclobutyl amine derivatives |
JP2007024970A (ja) * | 2005-07-12 | 2007-02-01 | Miyakawa:Kk | 液晶表示装置の開口効率を上昇させるための樹脂レンズ製造法及びその製造装置 |
US20090000437A1 (en) * | 2005-07-14 | 2009-01-01 | Provo Craft And Novelty, Inc. | Methods for Cutting |
US8168793B2 (en) | 2005-07-26 | 2012-05-01 | Portela & Ca., S.A. | Nitrocatechol derivatives as COMT inhibitors |
FR2889525A1 (fr) * | 2005-08-04 | 2007-02-09 | Palumed Sa | Nouveaux derives de polyquinoleines et leur utilisation therapeutique. |
US20070048384A1 (en) * | 2005-08-26 | 2007-03-01 | Joerg Rosenberg | Pharmaceutical compositions |
WO2007061862A2 (en) * | 2005-11-18 | 2007-05-31 | Janssen Pharmaceutica N.V. | 2-keto-oxazoles as modulators of fatty acid amide hydrolase |
JP4738419B2 (ja) * | 2005-11-30 | 2011-08-03 | 富士フイルムRiファーマ株式会社 | アミロイドの凝集及び/又は沈着に起因する疾患の診断薬及び治療薬 |
US20100285157A1 (en) * | 2006-02-20 | 2010-11-11 | Asahi Breweries, Ltd | Granules, tablets and method of producing the same |
GB0606774D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Ag | Organic compounds |
EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
PE20080906A1 (es) | 2006-08-17 | 2008-07-05 | Kemia Inc | Derivados heteroarilo como inhibidores de citocina |
US8486979B2 (en) * | 2006-12-12 | 2013-07-16 | Abbvie Inc. | 1,2,4 oxadiazole compounds and methods of use thereof |
US20080167286A1 (en) * | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
JP2008162955A (ja) * | 2006-12-28 | 2008-07-17 | Chugai Pharmaceut Co Ltd | バリン含有高密度顆粒剤 |
ES2597705T3 (es) | 2007-01-31 | 2017-01-20 | Bial - Portela & Ca., S.A. | Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico |
PE20081891A1 (es) | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
TWI503128B (zh) * | 2007-07-31 | 2015-10-11 | Ajinomoto Kk | A granule preparation containing an amino acid with excellent taste |
EP3311813B1 (en) | 2007-08-27 | 2019-08-07 | Dart Neuroscience (Cayman) Ltd | Therapeutic isoxazole compounds |
JP4976500B2 (ja) * | 2007-09-19 | 2012-07-18 | アサヒグループホールディングス株式会社 | 漢方エキス、生薬エキスあるいは天然物抽出エキスまたはそれらの混合物等の天然物由来物質を含有する顆粒物の製造方法およびその顆粒物から製造する錠剤の製造方法 |
JP2011513301A (ja) * | 2008-02-28 | 2011-04-28 | バイアル−ポルテラ アンド シーエー,エス.エー. | 難溶性薬剤のための医薬組成物 |
ES2565080T3 (es) | 2008-03-17 | 2016-03-31 | Bial-Portela & Ca, S.A. | Formas cristalinas de 5-[3-(2,5-dicloro-4,6-dimetil-1-oxi-piridin-3-il)-[1,2,4]oxadiazol-5-il]-3-nitrobenceno-1,2-diol |
AU2009277196B2 (en) | 2008-07-29 | 2015-06-18 | Bial - Portela & Ca., S.A. | Administration regime for nitrocatechols |
US8827197B2 (en) * | 2008-11-04 | 2014-09-09 | Microgreen Polymers Inc | Apparatus and method for interleaving polymeric roll for gas impregnation and solid-state foam processing |
PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
AU2010231962B2 (en) | 2009-04-01 | 2015-05-21 | Bial - Portela & Ca., S.A. | Pharmaceutical formulations comprising nitrocatechol derivatives and methods of making the same |
KR101868326B1 (ko) | 2010-03-04 | 2018-06-19 | 오리온 코포레이션 | 파킨슨병의 치료를 위한 레보도파, 카르비도파 및 엔타카폰의 용도 |
US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
PL2791134T3 (pl) | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
-
2010
- 2010-03-31 PT PT10713380T patent/PT2413912T/pt unknown
- 2010-03-31 ES ES10713380T patent/ES2730678T3/es active Active
- 2010-03-31 CA CA2757411A patent/CA2757411C/en active Active
- 2010-03-31 WO PCT/PT2010/000014 patent/WO2010114404A1/en active Application Filing
- 2010-03-31 TR TR2019/08590T patent/TR201908590T4/tr unknown
- 2010-03-31 KR KR1020187024054A patent/KR102329271B1/ko active IP Right Grant
- 2010-03-31 JP JP2012503350A patent/JP5864409B2/ja active Active
- 2010-03-31 KR KR20117026011A patent/KR20120027197A/ko active Search and Examination
- 2010-03-31 US US12/750,956 patent/US9132094B2/en active Active
- 2010-03-31 KR KR1020217001609A patent/KR20210009441A/ko not_active Application Discontinuation
- 2010-03-31 CN CN201610250582.8A patent/CN105878242A/zh active Pending
- 2010-03-31 AU AU2010231961A patent/AU2010231961B2/en active Active
- 2010-03-31 RU RU2016152167A patent/RU2701731C2/ru active
- 2010-03-31 EP EP10713380.3A patent/EP2413912B1/en active Active
- 2010-03-31 KR KR1020177009828A patent/KR102023255B1/ko active IP Right Grant
- 2010-03-31 DK DK10713380.3T patent/DK2413912T3/da active
- 2010-03-31 MX MX2011010415A patent/MX340360B/es active IP Right Grant
- 2010-03-31 PL PL10713380T patent/PL2413912T3/pl unknown
- 2010-03-31 CN CN201080022653.XA patent/CN102448444B/zh active Active
- 2010-03-31 RU RU2011144145/15A patent/RU2011144145A/ru not_active Application Discontinuation
- 2010-03-31 BR BRPI1014865-5A patent/BRPI1014865B1/pt active IP Right Grant
-
2015
- 2015-08-13 US US14/825,600 patent/US10071085B2/en active Active
- 2015-08-27 JP JP2015168152A patent/JP6239561B2/ja active Active
-
2018
- 2018-07-31 US US16/050,602 patent/US10583130B2/en active Active
-
2020
- 2020-03-05 US US16/809,662 patent/US20210023067A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI1014865A2 (pt) | "composição e formulação farmacêutica comreendendo derivados de nitrocatecol, e, método para fabricar uma composição ou formulação farmacêutica" | |
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
BRPI0817423A2 (pt) | Processos para a preparação de um composto, para a preparação de uma formulação farmacêutica, e para a preparação de um intermediário de um composto, e, composto | |
IL208203A (en) | Annotations of 3,2-Dihydro-Pyrido-4,1-Exazine and 3,2-Dihydro-4-Oxa-9,1-Diazapananthrene, Preparation Processes and Pharmaceutical Preparations | |
BRPI1013984A2 (pt) | composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto. | |
BRPI0815387A2 (pt) | composição farmacêutica, método para fazer uma composição farmacêutica e método de tratar uma condição | |
BRPI1011764A2 (pt) | composição farmacêutica, e, método para preparar uma composição farmacêutica | |
BRPI0908173A2 (pt) | composição para cuidado pessoal, e, método para fabricar uma composição ou uma formulação antimicrobiana para cuidado pessoal | |
BRPI0812064A2 (pt) | Formulação farmacêutica, tabletes, e, processo para a produção de uma formulação farmacêutica | |
BRPI0917705A2 (pt) | composto, pró-droga, composição farmacêutica, método para tratar ou prevenir uma doença ou condição, e, uso do composto | |
BRPI0819218A2 (pt) | Métodos, estojos e composições para administração de compostos farmacêuticos | |
BRPI0905717A2 (pt) | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica | |
BRPI0819755A2 (pt) | composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória | |
BRPI1016132A2 (pt) | composição, formulação farmacêutica, método para fabricar uma formulação farmacêutica estável. | |
BRPI0818680A2 (pt) | composição farmacêutica, preparação farmacêutica, e método para preparar um forma de dosagem oral farmacêutica | |
EP2130552A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING AN ANTI-GRP78 ANTIBODY AS AN ACTIVE SUBSTANCE | |
BRPI0818533A2 (pt) | composto, composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0922174A2 (pt) | preparação farmacêutica, uso de uma preparação, e, método para preparar uma preparação farmacêutica | |
BR112012003842A2 (pt) | composição farmacêutica, método de formulação e uso da mesma | |
BRPI0816320A2 (pt) | Composto, formulação farmacêutica, uso de um composto, método de tratamento de uma doença, produto de combinação, e, processos para a preparação deu um composto, de uma formulação farmacêutica, e de um produto de combinação | |
BRPI0912539A2 (pt) | composto, composição farmacêutica , método para tratar uma doença, e, uso do composto. | |
BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
BR112012003280A2 (pt) | composição farmacêutica para administração oral, método para tratar uma doença, uso do composto, e, composto. | |
IL195813A0 (en) | Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them | |
BRPI0914371A2 (pt) | "composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo, e produto de combinação" |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2010, OBSERVADAS AS CONDICOES LEGAIS. |